Year |
Citation |
Score |
2012 |
Cecchi F, Pajalunga D, Fowler CA, Uren A, Rabe DC, Peruzzi B, Macdonald NJ, Blackman DK, Stahl SJ, Byrd RA, Bottaro DP. Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling. Cancer Cell. 22: 250-62. PMID 22897854 DOI: 10.1016/J.Ccr.2012.06.029 |
0.652 |
|
2011 |
Cecchi F, Pajalunga D, Fowler A, Rabe DC, Peruzzi B, MacDonald NJ, Blackman DK, Stahl SJ, Byrd A, Bottaro DP. A hepatocyte growth factor antagonist engineered by site-directed mutagenesis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10528. PMID 28021761 DOI: 10.1200/Jco.2011.29.15_Suppl.10528 |
0.685 |
|
2010 |
Cecchi F, Pajalunga D, McNeil B, Rabe D, Fowler A, Liu Y, Gagnon CR, Kallender H, Shah MA, Getzenberg R, Schoenberg M, Martin A, Srinivasan R, Linehan WM, Byrd RA, et al. Abstract SY23-03: Oncogenic signal transduction via the hepatocyte growth factor/Met receptor kinase pathway Cellular and Molecular Biology. DOI: 10.1158/1538-7445.Am10-Sy23-03 |
0.669 |
|
2010 |
Cecchi F, Pajalunga D, Rabe DC, Peruzzi B, Fowler AC, Blackman DK, MacDonald N, Stahl SJ, Byrd AR, Bottaro DP. Abstract 342: A hepatocyte growth factor antagonist engineered by disruption of heparan sulfate binding Cancer Research. 70: 342-342. DOI: 10.1158/1538-7445.Am10-342 |
0.677 |
|
2009 |
Cecchi F, Pajalunga D, Rabe D, Fowler AC, MacDonald N, Blackman DK, Stahl SJ, Byrd AR, Bottaro DP. Abstract B228: A hepatocyte growth factor antagonist engineered by targeted disruption of heparan sulfate binding Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B228 |
0.749 |
|
Show low-probability matches. |